Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Ovarian Neoplasms

Free Subscription 13.05.2019 1 BMC Cancer 1 Cancer 1 Cancer Res 1 Clin Cancer Res 1 Gynecol Oncol 2 Histopathology 1 Hum Pathol 2 Int J Cancer 2 Int J Oncol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Cancer

1. DA COSTA AABA, do Canto LM, Larsen SJ, Ribeiro ARG, et al
   Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
   BMC Cancer. 2019;19:422.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

2. PINSKY PF, Black A, Daugherty SE, Hoover R, et al
   Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
   Cancer. 2019 May 8. doi: 10.1002/cncr.32176.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

3. MUKHERJEE A, Huynh V, Gaines K, Reh WA, et al
   Targeting the High Mobility Group Box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin.
   Cancer Res. 2019 May 6. pii: 0008-5472.CAN-19-0542.
   PubMed     Text format     Abstract available
   
   

   
   Clin Cancer Res

4. TAO JJ, Cangemi NA, Makker V, Cadoo K, et al
   First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
   Clin Cancer Res. 2019 May 8. pii: 1078-0432.CCR-19-1065.
   PubMed     Text format     Abstract available
   
   

   
   Gynecol Oncol

5. HOPPENOT C, Peters P, Cowan M, Moore ED, et al
   Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
   Gynecol Oncol. 2019 May 2. pii: S0090-8258(19)31183.
   PubMed     Text format     Abstract available
   
   

   
   Histopathology

6. WANG L, Rambau PF, Kelemen LE, Anglesio MS, et al
   Nuclear beta-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.
   Histopathology. 2019;74:452-462.
   PubMed     Text format     Abstract available
   
   
7. MCCLUGGAGE WG, Chong AS, Attygalle AD, Clarke BA, et al
   Expanding the morphological spectrum of ovarian microcystic stromal tumour.
   Histopathology. 2019;74:443-451.
   PubMed     Text format     Abstract available
   
   

   
   Hum Pathol

8. ZHANG Y, Tao L, Yin C, Wang W, et al
   Ovarian microcystic stromal tumor with undetermined potential: Case study with molecular analysis and literature review.
   Hum Pathol. 2018 Feb 16. pii: S0046-8177(18)30053.
   PubMed     Text format     Abstract available
   
   

   
   Int J Cancer

9. LI J, Wen WX, Eklund M, Kvist A, et al
   Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
   Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
   PubMed     Text format     Abstract available
   
   
10. KLEIBLOVA P, Stolarova L, Krizova K, Lhota F, et al
    Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

11. KIM BI, Kim JH, Sim DY, Nam M, et al
    Inhibition of JAK2/STAT3 and activation of caspase9/3 are involved in KYS05090Sinduced apoptosis in ovarian cancer cells.
    Int J Oncol. 2019 May 3. doi: 10.3892/ijo.2019.4795.
    PubMed     Text format     Abstract available
    
    
12. BU S, Li B, Wang Q, Gu T, et al
    Epithelial ovarian cancer stemlike cells are resistant to the cellular lysis of cytokineinduced killer cells via HIF1Amediated downregulation of ICAM1.
    Int J Oncol. 2019 May 3. doi: 10.3892/ijo.2019.4794.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: